TY  - GEN

T1  - 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

PY  - 2021/09/01

AU  - Cork MJ

AU  - Thaçi D

AU  - Eichenfield L

AU  - Arkwright PD

AU  - Chen Z

AU  - Delevry D

AU  - O’Malley JT

AU  - Bansal A

ED  - 

Y2  - 2024/12/22

ER  -